Compare Abeona Therapeutics Inc (ABEO) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Standard Lithium Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Standard Lithium Ltd trades at $2.53 (market cap $592.60M). The key difference: Standard Lithium Ltd is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | SLI | |
|---|---|---|
Market Cap | $373.32M | $592.60M |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $5.65 |
52-Week Low | $4.17 | $2.29 |
Enterprise Value | $228.22M | $451.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Standard Lithium (SLI) trades at $2.68, down 1.47% on the day, with a bearish technical signal from moving averages despite some bullish oscillators. The company reported a net loss of $48.40 million in 2025, with negative ROE and ROA, but maintains a P/B ratio of 1.8. Recent news highlights progress on its South West Arkansas lithium project, including a $225 million DOE grant and key construction contracts, positioning it for a final investment decision in 2026.
The investment case hinges on successful project execution and lithium market dynamics, with 100% analyst buy ratings signaling strong growth potential. Key risks include persistent negative cash flow from operations, high capital expenditures, and execution delays. Upside depends on timely project completion and favorable lithium pricing, while downside risks involve funding gaps and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
